A Decade of Active Surveillance in the PRIAS Study : an Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment

Published on Dec 1, 2016in European Urology17.947
· DOI :10.1016/J.EURURO.2016.06.007
Leonard P. Bokhorst12
Estimated H-index: 12
(Erasmus University Medical Center),
Riccardo Valdagni51
Estimated H-index: 51
+ 4 AuthorsMonique J. Roobol76
Estimated H-index: 76
(Erasmus University Medical Center)
Sources
Abstract
Abstract Background The Prostate Cancer Research International Active Surveillance (PRIAS) study was initiated a decade ago to study the most optimal selection and follow-up of men on active surveillance (AS). Objective We report on 10 yr of follow-up of men on AS in the PRIAS study and evaluate if criteria used to recommend a switch to active treatment truly predict unfavorable outcome on subsequent radical prostatectomy (RP). Design, setting, and participants Men with low-risk prostate cancer were included and followed prospectively on AS. Follow-up consisted of regular prostate-specific antigen (PSA) tests, digital rectal examinations, and biopsies. Men with Gleason >3+3, more than two positive biopsy cores, or stage higher than cT2 were advised to switch to active treatment (until 2014, a PSA doubling time [PSA DT] of 0–3 yr was also used). Outcome measurements and statistical analysis Reclassification rates, treatment after discontinuation, and outcome on RP after discontinuing AS were reported. Regression analysis on the outcome of RP was used to evaluate the predictive value of criteria currently used to recommend a switch to active treatment. Kaplan-Meier and competing risk analysis were used to report discontinuation rates over time and long-term oncologic end points. Results and limitations A total of 5302 men were included in PRIAS across 18 countries. Reclassification rates remained stable on all subsequent biopsies, with 22–33% of men having either Gleason >3+3 or more than two positive cores on any repeat biopsy. At 5 and 10 yr of follow-up, 52% and 73% of men, respectively, had discontinued AS, most of them because of protocol-based reclassification. A third of men undergoing subsequent RP had favorable pathologic tumor features (Gleason 3+3 and pT2). Of the criteria used to recommend a switch to active treatment, more than two positive cores and a PSA DT of 0–3 yr were not predictive of unfavorable pathologic outcome on RP. Conclusions A substantial group of men discontinued AS without subsequent unfavorable tumor features on RP; therefore, we propose Gleason upgrading and cT3 as the only indicators for an immediate switch to active treatment. Surrogate indicators (eg, more than two positive cores and a fast-rising PSA) should not trigger immediate active treatment but rather further investigation to confirm the suspicion of higher risk disease. Patient summary We confirmed the safety of active surveillance as a treatment option for men with low-risk prostate cancer; however, some changes could be made to the follow-up protocol to safely increase the number of men who remain on active surveillance.
📖 Papers frequently viewed together
692 Citations
1,180 Citations
316 Citations
References21
Newest
#1Leonard P. Bokhorst (Erasmus University Medical Center)H-Index: 12
#2Inari Lepistö (HYKS: Helsinki University Central Hospital)H-Index: 1
Last. Antti Rannikko (HYKS: Helsinki University Central Hospital)H-Index: 30
view all 13 authors...
Objective To study the risk of serial prostate biopsies on complications in men on active surveillance (AS) and determine the effect of complications on receiving further biopsies. Patients and methods In the global Prostate cancer Research International: Active Surveillance (PRIAS) study, men are prospectively followed on AS and repeat prostate biopsies are scheduled at 1, 4, and 7 years after the diagnostic biopsy, or once yearly if prostate-specific antigen-doubling time is <10 years. Data on...
33 CitationsSource
#1Donna P. Ankerst (TUM: Technische Universität München)H-Index: 44
#2Jing Xia (Fred Hutchinson Cancer Research Center)H-Index: 9
Last. Daniel W. Lin (UW: University of Washington)H-Index: 73
view all 15 authors...
Abstract Background Men on active surveillance (AS) face repeated biopsies. Most biopsy specimens will not show disease progression or change management. Such biopsies do not contribute to patient management and are potentially morbid and costly. Objective To use a contemporary AS prospective trial to develop a tool to predict AS biopsy outcomes. Design, setting, and participants Biopsy samples (median: 2; range: 2–9 per patient) from 859 men participating in the Canary Prostate Active Surveilla...
38 CitationsSource
#1Caroline M. Moore (UCL: University College London)H-Index: 34
#2Chris Parker (The Royal Marsden NHS Foundation Trust)H-Index: 83
The aimof active surveillance for localised prostate cancer is to offer timely treatment to[6_TD$DIFF] those men who need it while avoiding the harms of unnecessary treatment in those with indolent disease. The safety of active surveillance has been documented in relatively large, mature cohort studies. For example, among the Toronto cohort of 993men followed for up to 19 yr, more than half have avoided treatment and just 2.8% have developed metastatic disease [1]. Since active surveillance was ...
2 CitationsSource
#1Leonard P. Bokhorst (Erasmus University Medical Center)H-Index: 12
#2Arnout R. Alberts (Erasmus University Medical Center)H-Index: 9
Last. Monique J. Roobol (Erasmus University Medical Center)H-Index: 76
view all 8 authors...
Abstract Background Men with prostate cancer on active surveillance (AS) are advised to follow strict follow-up schedules and switch to definitive treatment on risk reclassification. However, some men might not adhere to these strict protocols. Objective To determine the number of noncompliers and disease reclassification rates in men not complying with the follow-up protocol of the Prostate Cancer Research International Active Surveillance (PRIAS) study. Design, setting, and participants A tota...
77 CitationsSource
#1Ivo G. Schoots (Erasmus University Medical Center)H-Index: 30
#1Ivo G. Schoots (Erasmus University Medical Center)H-Index: 13
Last. M. G. Myriam Hunink (Harvard University)H-Index: 93
view all 6 authors...
Context: Multiparametric magnetic resonance imaging (MRI) of the prostate may improve the diagnostic accuracy of prostate cancer detection in MRI-targeted biopsy (MRI-TBx) in comparison to transrectal ultrasound-guided biopsy (TRUS-Bx). Objective: Systematic review and meta-analysis of evidence regarding the diagnostic benefits of MRI-TBx versus TRUS-Bx in detection of overall prostate cancer (primary objective) and significant/insignificant prostate cancer (secondary objective). Evidence acquis...
404 CitationsSource
#1Jeffrey J. Tosoian (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 29
#2Mufaddal Mamawala (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 13
Last. H. Ballentine Carter (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 79
view all 7 authors...
PurposeTo assess long-term outcomes of men with favorable-risk prostate cancer in a prospective, active-surveillance program.MethodsCurative intervention was recommended for disease reclassification to higher cancer grade or volume on prostate biopsy. Primary outcomes were overall, cancer-specific, and metastasis-free survival. Secondary outcomes were the cumulative incidence of reclassification and curative intervention. Factors associated with grade reclassification and curative intervention w...
316 CitationsSource
#1Charlotte F. Kweldam (EUR: Erasmus University Rotterdam)H-Index: 16
#2Mark F. Wildhagen (EUR: Erasmus University Rotterdam)H-Index: 43
Last. Geert J.L.H. van Leenders (EUR: Erasmus University Rotterdam)H-Index: 57
view all 4 authors...
Objectives To assess the metastasis-free survival (MFS) and disease-specific survival (DSS) in men with Gleason score ≤6 prostate cancer at radical prostatectomy (RP). Patients and Methods We included 1101 consecutive RP patients operated between March 1985 to July 2013 at a single institution. The outcome variables were MFS and DSS. The postoperative survival was estimated by the Kaplan–Meier method. Results The Gleason score distribution of the study population (1101 patients) was Gleason scor...
41 CitationsSource
#1Annerleim Walton Diaz (NIH: National Institutes of Health)H-Index: 4
#2Nabeel Shakir (NIH: National Institutes of Health)H-Index: 13
Last. Peter A. Pinto (NIH: National Institutes of Health)H-Index: 65
view all 20 authors...
Introduction: We evaluated the performance of multiparametric prostate magnetic resonance imaging (mp-MRI) and MRI/transrectal ultrasound (TRUS) fusion–guided biopsy (FB) for monitoring patients with prostate cancer on active surveillance (AS). Materials and methods: Patients undergoing mp-MRI and FB of target lesions identified on mp-MRI between August 2007 and August 2014 were reviewed. Patients meeting AS criteria (Clinical stage T1c, Gleason grade r6, prostate-specific antigen density r0.15,...
108 CitationsSource
#1Stacy Loeb (NYU: New York University)H-Index: 68
#2Sophie Bruinsma (EUR: Erasmus University Rotterdam)H-Index: 13
Last. Monique J. Roobol (EUR: Erasmus University Rotterdam)H-Index: 76
view all 8 authors...
Abstract Context Active surveillance (AS) is an important strategy to reduce prostate cancer overtreatment. However, the optimal criteria for eligibility and predictors of progression while on AS are debated. Objective To review primary data on markers, genetic factors, and risk stratification for patient selection and predictors of progression during AS. Evidence acquisition Electronic searches were conducted in PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) fr...
89 CitationsSource
#1S. BruinsmaH-Index: 4
#1Sophie BruinsmaH-Index: 13
Last. Monique J. RoobolH-Index: 76
view all 4 authors...
4 CitationsSource
Cited By181
Newest
#1Yoichiro Tohi (Kagawa University)H-Index: 4
#2Takuma Kato (Kagawa University)H-Index: 5
Last. Koji InoueH-Index: 18
view all 0 authors...
Abstract null null Objectives null This study aimed to evaluate how health-related quality of life (HRQOL) is related to repeat protocol biopsy compliance. null null null Materials and methods null We conducted a retrospective analysis using data from a prospective cohort in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study between January 2010 and August 2019. We used the Short Form 8 Health Survey (SF-8), as patient-reported outcomes, to assess HRQOL at AS enr...
Source
Abstract null null Background and aims null Overdiagnosis of prostate cancer (PCa) should be minimized. We wanted to evaluate the diagnostic performance of the prostate health index density (PHID) and compare it with that of the prostate health index (PHI) alone and of the prostate-specific antigen density (PSAD). null null null Materials and methods null 232 men scheduled for a prostate biopsy (prostate-specific antigen level: 2-10 µg/L), were enrolled. PHI, PHID and PSAD were evaluated conside...
Source
#1Agostino Antonio Santoro (UCSC: Catholic University of the Sacred Heart)
#2Luca Di Gianfrancesco (UCSC: Catholic University of the Sacred Heart)H-Index: 7
Last. Angelo Totaro (UCSC: Catholic University of the Sacred Heart)H-Index: 12
view all 11 authors...
Prostate cancer is the second most commonly diagnosed cancer in man. Since the first MRI was performed, enormous progress has been made in diagnosis, treatment, and follow up of PCa, mainly due to multiparametric prostatic MRI (mpMRI). Although mpMRI has become the best imaging tool for identifying PCa, some limitations still exist. Prostate imaging with mpMRI is, to date, the best way to locate suspicious lesions to trigger prostate biopsy, plan active surveillance, or definitive treatment. In ...
Source
Resumen null null Objetivo null Determinar si el protocolo de vigilancia activa (VA) de nuestra institucion es una estrategia adecuada para minimizar el sobretratamiento del cancer de prostata. null null null Material y metodos null Analisis retrospectivo de 516 pacientes en VA tras el diagnostico de cancer de prostata. La poblacion se dividio en «VA por protocolo» vs. «VA inducida», dependiendo del cumplimiento de los criterios de inclusion del protocolo. Las prostatectomias radicales despues d...
Source
#1Sina Monfared (BIDMC: Beth Israel Deaconess Medical Center)
#2Aaron Fleishman (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
Last. Boris Gershman (BU: Boston University)
view all 9 authors...
Abstract Background There are limited data to support the safety of active surveillance in men with favorable-intermediate risk prostate cancer due only to a prostate specific antigen (PSA) above 10 ng/ml. We therefore evaluated the impact of pretreatment PSA on risk-stratification in men with Gleason 6 prostate cancer. Methods We identified men aged 18 to 75 with cT1-2cN0cM0, pre-treatment PSA Results A total of 75,566 patients were included in the cohort. In unadjusted analyses, patients with ...
Source
#1Lothar WeißbachH-Index: 1
#2Edith A. BoedefeldH-Index: 1
Last. Jan Herden (Praxis)H-Index: 7
view all 0 authors...
Die Active Surveillance (AS) hat sich bei den dafur geeigneten Prostatakarzinomen (PCa) im Gegensatz zu Nordamerika oder Schweden bei uns noch nicht durchgesetzt. Die von der Leitlinie vorgegebenen strengen Eingangskriterien werden an den niedrigen Versorgungszahlen nichts andern. Es gibt verschiedene Ursachen dafur, die Radikaloperation weiterhin zu praferieren. In der Konsequenz fuhrt die PSA-Bestimmung bei der Fruherkennung so zu einer hohen Zahl von Uberbehandlungen. Es gilt zu prufen, ob di...
Source
Resume Introduction L’objectif de cette etude etait de determiner l’impact des marges chirurgicales positives (MCP) lors d’une prostatectomie totale (PT) pour cancer de prostate (CaP) localise ou localement avance sur les resultats oncologiques. Methodes Il s’agissait d’une etude retrospective monocentrique. Tous les patients traites par prostatectomie totale entre janvier 2004 et decembre 2018 pour cancer de prostate localise ou localement avance ont ete inclus. Les donnees preoperatoires, post...
Source
#1Lothar WeißbachH-Index: 1
#2Edith A. BoedefeldH-Index: 1
Last. Jan HerdenH-Index: 7
view all 0 authors...
Source
#1Giancarlo Marra (UNITO: University of Turin)H-Index: 13
#2Timo F.W. SoeterikH-Index: 3
Last. Xavier Cathelineau (Paris V: Paris Descartes University)H-Index: 51
view all 14 authors...
Abstract Background To date, only one trial compared focal therapy and active surveillance (AS) for low-risk prostate cancer (PCa). In addition, long-term outcomes of focal cryotherapy (FC) are lacking. Objective Our aim was to evaluate long-term outcomes of FC and compare them with AS. Design, setting, and participants We included two prospective series of 121 (FC) and 459 (AS) consecutive patients (2008–2018) for low- to intermediate-risk PCa. Outcome measurements and statistical analysis Stud...
Source
#1H.B. Luiting (EUR: Erasmus University Rotterdam)H-Index: 4
#2Sebastiaan Remmers (EUR: Erasmus University Rotterdam)H-Index: 6
Last. Monique J. Roobol (EUR: Erasmus University Rotterdam)H-Index: 76
view all 10 authors...
BACKGROUND The reduction of overtreatment by active surveillance (AS) is limited in patients with low-risk prostate cancer (PCa) due to high rates of patients switching to radical treatment. MRI improves biopsy accuracy and could therewith affect inclusion in or continuation of AS. We aim to assess the effect of MRI with target biopsies on the total rate of patients discontinuing AS, and in particular discontinuation due to Grade Group (GG) reclassification. METHODS Three subpopulations included...
Source